

# **BIONETICS**

Mutagenic Evaluation of Compound FDA 73-4 (Potassium Sorbate)

11/25/74

MUTAGENIC EVALUATION OF COMPOUND FDA 73-4

Potassium Jorbate

5516 Nicholson L Kensington, Maryl 20795 LBI PROJECT #2468

MUTAGENIC EVALUATION OF COMPOUND FDA 73-4

Potassium Jorbate

### SUBMITTED TO

FOOD & DRUG ADMINISTRATION
DEPARTMENT OF HEALTH, EDUCATION AND WELFARE
ROCKVILLE, MARYLAND

### SUBMITTED BY

LITTON BIONETICS, INC. 5516 NICHOLSON LANE KENSINGTON, MARYLAND

NOVEMBER 25, 1974



o or disease.

# TABLE OF CONTENTS

•		Page No.
Evalua	tion Summary	1
I.	Objective	2
II.	Materials	. 2
III.	Methods	3 .
IV.	Solubility Properties	7
٧.	Toxicity and Dosage Determinations	8
VI.	Non-activation Plate Tests	9
VII.	Activation Plate Tests	11
VIII.	Non-activation Suspension Tests/Salmonella	17
IX.	Activation Suspension Tests/Salmonella	19
X.	Non-activation Suspension Tests/Saccharomyces	25
XI.	Activation Suspension Tests/Saccharomyces	27
XII.	Summary of Test Results	35
XIII.	Interpretation and Conclusions	47
Append	ix - Summary of Tests Evaluating DMSO for Genetic Activity in Salmonella and Saccharomyces	



A Control of the

The second second

a second

### **EVALUATION SUMMARY**

Compound FDA 73-4, Potassium Sorbate, did not exhibit any genetic activity in the tests used in this evaluation.



DATE:

November 25, 1974

SPONSOR:

Food and Drug Administration, Contract Number 223-74-2104

SUBJECT:

Mutagenic Evaluation of Compound FDA 73-4

### I. OBJECTIVE

The objective of this study was to assess the genetic activity of the test material in microbial assays with and without the addition of mammalian metabolic enzyme preparations.

### II. MATERIALS

### A. <u>Test Material</u>

Potassium Sorbate

Pfizer #72683

### B. <u>Tissue Homogenates and Supernatants</u>

The tissue homogenates and 9,000 x g supernatants were prepared from liver, lung and testes of the following mammalian species: Mouse - ICR random bred adult males; rat - Sprague-Dawley adult males; and primate - Macaca mulatta adult males.

### C. <u>Indicator Organisms</u>

The indicator organisms used for all tests are described below:

- Saccharomyces cerevisiae, strain D4:  $\alpha$  ade 2-2 try 5-12 a, ade 2-1, try 5-27
- <u>Salmonella</u> <u>typhimurium</u>, strains:

```
TA-1535; <a href="his6">his6</a>, <a href="his6">uvrB</a>, <a href="rfa">rfa</a> (missense mutation)
TA-1537; <a href="his6">his6</a>, <a href="his6">uvrB</a>, <a href="rfa">rfa</a> ( + frameshift mutation)
```

### D. - Reaction Mixture

The following reaction mixture was employed in the activation tests:



•	Component	Final Con	centration/ml
1.	TPN (sodium salt)		6 <u>ս</u> М
2.	Isocitric acid		49 uM
3.	Tris buffer, pH 7.4		28 uM
4.	MgCl <sub>2</sub>		1.7 uM 🕏
5.	Isocitric dehydrogenase		1.0 Unit
6.	Tissue homogenate or cell fraction		72 mg

Components 1-4 were combined and frozen as a "core" reaction mixture to which the other components were added just prior to use.

### E. <u>Positive Control Compounds</u>

Table 1 lists chemicals for positive controls in the direct and activation assays.

# TABLE 1 POSITIVE CONTROLS USED IN DIRECT AND ACTIVATION ASSAYS

ASSAY	CHEMICAL	SOLVENT	PROBABLE MUTAGENIC SPECIFICITY b
Non-activation	Ethylmethane sulfonate	Water or saline	BPS
•	2-Nitrosofluorene	Dimethylsulfoxide <sup>C</sup>	FS
	Quinacrine or Quinacrine mustard	Water or saline	FS
Activation	Dimethylnitrosamine	Water or saline	BPS
	- 2-Acetylaminofluorene	Dimethylsulfoxide <sup>C</sup>	FS

a Concentrations given in the Results Section.

### III. METHODS

### A. <u>Toxicity</u>

The solubility, toxicity and doses for all chemicals were determined prior to screening.

Each chemical was tested for survival against strains TA-1537 and D4 over a range of doses to determine the 50% survival dose. Bacteria were tested in phosphate buffer, pH 7.4, for one hour at 37°C on a shaker. Yeasts were tested in phosphate buffer, pH 7.4, for four hours at 30°C on a shaker. The 50% survival dose was determined from the survival curve and the 1/4 and 1/2 50% doses calculated.



**b** BPS = base-pair substitution; FS = frameshift.

C Previously shown to be non-mutagenic, see Appendix.

If no toxicity was obtained for a chemical with a given strain, then a maximum dose of 5% (w/v) was used against the strain.

Unless otherwise specified, the doses calculated for the tests in buffer were applied to the activation tests. The solubility of the test chemical under treatment conditions is stated in the Results Section.

### B. <u>Plate Tests</u>

Only three bacteria strains were tested in qualitative plate tests. In the non-activation procedure, approximately 109 cells of a log phase culture of the bacterial indicator strains were spread over the surface of a minimal plate, and a measured amount of the test chemical was placed in the center of the test plate. In activation tests, the test chemical was added to the cells, and an aliquot of the mixture was spread on the surface of the test plate. The reaction mixture (0.1 ml) plus tissue extract was then spotted on the surface of the plate. Positive and solvent controls were included. All plates were incubated at 37°C for four days and then scored. Each compound (Test, Positive Control and Solvent Control) was done in duplicate. The results were scored as + or -. Concentrations of the positive control compounds are listed in the Results Section.

### C. Suspension Tests

#### Non-activation

Log-phase bacteria and stationary-phase yeast cultures of the indicator organisms were grown in complete broth, washed and resuspended in 0.9% saline to densities of 1 x  $10^9$  cells/ml and 5 x  $10^7$  cells/ml, respectively. This constituted the working stock for tests of a group of test chemicals and their respective controls. Tests were conducted in 30 ml plastic tissue culture flasks. Cells plus appropriate volume(s) of the test chemical were added to the flasks to give a final volume of 2 ml. Solvent replaced the test chemical in the negative controls. Treatment was at 30°C for four hours for yeast tests and at 37°C for one hour for bacterial tests. All flasks were shaken during treatment. Following treatment, the flasks were set in ice. Aliquots of cells were removed, diluted in sterile saline (4°C) and plated on the appropriate complete media. Undiluted samples from flasks containing the bacteria were plated on minimal selective medium. Samples from a 10-1 dilution of treated cells were plated on the selected media for enumeration of gene conversion with strain D4. Bacterial plates were scored after incubation for 48 hours at 37°C. The yeast plates were incubated at 30°C for 3-5 days before scoring.

#### Activation

Bacteria and yeast cells were grown and prepared as described in the non-activation tests except that the cell densities were increased approximately five-fold for working stock suspensions. Measured amounts of the test and



4

control chemicals plus 0.25 ml of the stock cell suspension were added to a 30 ml plastic tissue homogenate. All flasks (bacteria and yeast) were incubated at 37°C with shaking. The treatment times as well as the dilutions, plating procedures and scoring of the plates were the same as described for non-activation tests.

### D. Preparation of Tissue Homogenates and 9,000 x g Cell Fractions

#### 1. Mice

Male mice (sufficient to provide the necessary quantities of organs for testes, lung and liver homogenates) were killed by cranial blow, decapitated and bled. The three organs were immediately dissected from the animal using aseptic techniques and placed in ice-cold 0.25 M sucrose buffered with Tris at pH of 7.4. Upon collection of the desired quantity of organs, they were washed twice with fresh buffered sucrose and completely homogenized with a motor-driven homogenizing unit at  $4^{\circ}$ C. The whole organ homogenate obtained from this step was divided into two samples. One sample was frozen at  $-80^{\circ}$ C and the other was centrifuged for 20 minutes at 9,000 x g in a refrigerated centrifuge. The supernatant from the centrifuged sample was retained and frozen at  $-80^{\circ}$ C. These two frozen samples were used for the activation studies.

#### 2. Rats

The same procedures as described for mice were used for this mammal.

#### 3. Primates

The liver, lungs and testes were aseptically removed from freshly killed adult male rhesus ( $\underline{M}$ .  $\underline{mulatta}$ ) monkeys. Each organ was cut into a number of pieces each sufficient for one week's studies. The tissues were labeled and frozen at -80°C until needed. Tissue homogenates and 9,000 x g supernatants were prepared as described for mice.

### E. Data Recording and Reporting

Following the specified incubation periods all population plates were scored by an automatic colony counter and the results from each plate of a set were recorded, in ink, in bound data books. Information necessary for identification of the specific experiment as well as the presence of any contaminant microorganisms was recorded with each set of plate counts. All minimal or other types of selective media plates were hand scored and the results recorded along with the respective population data. For bacteria strains the number of colonies recorded from either the population or selective plates represents that number in 1 ml of test suspension plated. The numbers recorded for the yeast strain D4 represent the number in 0.5 ml of test suspension plated.



Frequencies were mechanically calculated and double checked. All data presented in the Results Section of this report consists of the actual sum of all raw data plate counts and only the frequencies are calculated figures.



0

100

.

CONTRACTOR OF THE PARTY OF THE

### IV. SOLUBILITY PROPERTIES OF THE TEST COMPOUND

- NAME OR DESCRIPTION OF TEST COMPOUND: FDA 73-4 Potassium Sorbate Pfizer #72683
- 2. TEST SOLVENT AND DESCRIPTION OF SOLUBILITY OF THE TEST CHEMICAL UNDER TREATMENT CONDITIONS: Stock solutions of this chemical were prepared in phosphate buffer, pH 7.4. The compound appeared completely soluble at treatment concentrations.
- 3. OTHER COMMENTS:



·		<b>D4</b>	TA-1537
	Dose No.	% Concentration	% Concentration
Range of concentrations of	1	1.	0.1
the test compound used to	2	2	0.5
determine the 50% survival level	3	3	1.0 2.5
	5	5	5.0
	Dose No.	% Survival	% Survival
Survival Results	Control	100	100
		100	100
Test Date: <u>8/13/74</u>	2	100	27
	3	100	45
	5	100 80	0 0
•	Dose	% Concentration	% Concentration
Concentrations of the test	Plate Test		2,50
chemical required for	⅓ 50% Survival		1.25
mutagenicity tests	철 50% Survival	<b></b>	2.50
	<u>Other</u>	H 5.00	

Project No. 2468

H 5.00 L 2.50

#### VI. NON-ACTIVATION PLATE TESTS

DATE: 9-19-74

			TA-1535		TA-1537		TA-1538	
Test	Compound	Concentration/plate	T-1 T	-2	T-1	T-2	T-1	T-2
PC	EMS	0.05 ml undi- luted chemical	>103 >	103				
	QM	0.25 mg			56	43 -	( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )	
	NF	0.25 mg					25	31
SC	SALINE	-	3 (	0	3	4		
•	DMSO	<10%			34 Tarjak		3	5

NOTE: PC

PC = positive control
SC = solvent control
T-1 = trial 1
T-2 = trial 2
EMS = ethyl methanesulfonate
QM = quinacrine mustard
NF = nitrosofluorene
DMSO = dimethyl sulfoxide
(c) = contamination present

DATE: 9/19/74

						•	<del></del>	
	,	TA-1535		TA-1537		TA-1538		
Test	Compound	Concentration	T-1	T-2	T-1	T-2	T-1	T-2
TC	FDA 73-4	2.5%	2	0	3	2	2	1

NOTE:

TC = test compound
T-1 = trial 1
T-2 = trial 2
(c) = contamination present

## VII. ACTIVATION PLATE TESTS

CDECTES	: Mouse			DATE: 9-19-						
SPECIES		·		TA-15	35_	TA-15	<u>37</u>	TA-1	538	
Test	Organ	Compound	Concentration/plate	T-1	T-2	T-1	T-2	T-1	T-2	
PC	Li	DMNA	25 µmoles	>10 <sup>2</sup> >	10 <sup>2</sup>					
		AAF	1.25 mg			· >10 <sup>2</sup> >	102	>102	>10 <sup>2</sup>	
	Lu	DMNA	25 umoles	7	3					
		AAF	1.25 mg			17	18	45	35	
	T	DMNA	25 µmoles	(c)	5					
		AAF	1.25 mg			23	16	16	13	
SC	·	DMNA	25 umoles	3	4				2.64	
	-	AAF	1.25 mg			15	19	17	14	
		Saline	-	3	4					
	· <b>-</b>	DMSO	<10%			12	14	15	13	

NOTE:

PC = positive control
SC = solvent and chemical controls
AAF = 2-acetylaminofluorene
DMNA = dimethylnitrosamine

= liver

= lung

= testes

T-1 = trial l

T-2 = trial 2 DMSO = dimethyl sulfoxide (c) = contamination present



SPECIE	SPECIES: Mouse DATE: 9/19/7									
		•		TA-	1535	TA-	1537	_TA-1	TA-1538	
Test	Organ	Compound	Concentration	T-1	T-2	T-1	T-2	T-1	T-2	
тс	Li	FDA 73-4	2.5%	2	4	17	23	18	21	
	Lu	FDA 73-4	2.5%	3	1	24	28	29	27	
	T	FDA 73-4	2.5%	2	4	19	17	25	25	

NOTE:

TC = test compound
Li = liver
Lu = lung
T = testes
T-1 = trial 1
T-2 = trial 2
(c) = contamination present

				DATE: 9-19-74								
SPECIES	:Rat	<u> </u>		TA-1535	TA-1537	TA-1538						
Test	Organ	Compound	Concentration/plate	T-1 T-2	T-1 T-2	T-1 T-2						
PC	Li	DMNA	25 µmoles	10 <sup>2</sup> > 10 <sup>2</sup>								
. •		AAF	1.25 mg		>10 <sup>2</sup> 30 <sup>2</sup>	10 <sup>2</sup> > 10 <sup>2</sup>						
		DMNA	25 µmoles	2 3								
		AAF	1.25 mg		17 8	28 20						
	т	- DMNA	25 <sub>µ</sub> moles	.3 6								
		AAF	1.25 mg		7 8	14 9						
SC		DMNA	25 umoles	3 4								
30		AAF	1.25 mg		15 19	17 14						
		Saline	-	3 4								
•		DMSO	<10%		12 14	15 13						

NOTE:

PC = positive control
SC = solvent and chemical controls
AAF = 2-acetylaminofluorene
DMNA = dimethylnitrosamine

= liver

= lung Lu

= testes

T-1 = trial 1
T-2 = trial 2
DMSO = dimethyl sulfoxide
(c) = contamination present



SPECIE	PECIES: Rat DATE: 9/19/7							19/74		
				TA-1	535	TA-1	537	TA-1	TA-1538	
Test	Organ	Compound	Concentration	T-1	T-2	T-1	T-2	т-1	T-2	
тс	Li	FDA 73-4	2.5%	3	4	30	14	27	25	
	Lu	FDA 73-4	2.5%	7	9	27	42	35	30	
	Т	FDA 73-4	2.5%	4	1	42	22	29	19	

NOTE:

TC = test compound
Li = liver
Lu = lung
T = testes
T-1 = trial 1
T-2 = trial 2
(c) = contamination present

SPECIES	S: Monkey			DATE: 9-19-74							
				TA-1535	TA-1537	TA-1538					
Test	Organ	Compound	Concentration/plate	T-1 T-2	T-1 T-2	T-1 T-2					
PC	Li	DMNA	25 µmoles	>10 <sup>2</sup> >10 <sup>2</sup>							
		AAF	1.25 mg		>10 <sup>2</sup> >10 <sup>2</sup>	10 <sup>2</sup> 10 <sup>2</sup>					
·	Lu	DMNA	25 µmoles	3 4							
		AAF	1.25 mg		10 8	13 10					
	, <b>T</b>	DMNA	25 µmoles	3 3							
		AAF	1.25 mg		10 7	וו ווו					
SC	-	DMNA	25 umoles	3 4							
•	-	AAF	1.25 mg		15 19	17 14					
	-	Saline		3 4							
	-	DMSO	<10%		12 14	15 13					

NOTE:

PC = positive control
SC = solvent and chemical controls
AAF = 2-acetylaminofluorene
DMNA = dimethylnitrosamine

= liver

Lu = lung = testes

T-1 = trial 1 T-2 = trial 2 DMSO = dimethyl sulfacide (c) = contamination present

Project ... 2468



SPECIE	S: Monkey .								DATE: 9/19/74					
			TA-1535			TA-1537			TA-1538					
Test	Organ organ	Compound	Concentration	T-1	T-2		T-1	T-2		T-1	T-2			
TC	Li	FDA 73-4	2.5%	3	0		15	12		26	18			
	Lu	FDA 73-4	2.5%	1	2		8	8		9	17			
	T	FDA 73-4	2.5%	3	1		4	6		15	17			

NOTE:

TC = test compound
Li = liver
Lu = lung
T = testes
T-1 = trial 1
T-2 = trial 2
(c) = contamination present

# VIII. NON-ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

DATE: 9-8-74

Test	Indicator Strain	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	his+ Revertants/10 <sup>8</sup> Survivors
PC	TA-1535	EMS	0.05 %	2.96	1,790	604.73
	TA-1537	QM	0.01 mg/ml	3.11	911	292.93
	TA-1538	NF	1.25 mg/ml	3.66	266	72.68
SC	TA-1535	SALINE	-	3.27	6	1.83
	TA-1537	SALINE	-	4.66	37	7.94
	TA-1538	DMS0	-	3.01	13	4.32

NOTE: PC = positive control

SC = solvent control

EMS = ethyl methanesulfonate

QM = quinacrine mustard

NF = nitrosofluorene

DMSO = dimethyl sulfoxide

(c) = contamination present

Project Number <u>2468</u>



# NON-ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

				DATE: 9/8/74						
Test	Indicator Strain	Compound	Concentration	Total Cells/ R mlx10 <sup>8</sup>	<u>his</u> + Revertants/ ml	his+ Revertants/10 <sup>8</sup> Survivors				
TC	TA-1535	FDA 73-4	Н	3.23(99)	8	2.48				
TC	TA-1535	FDA 73-4	L	3.12(95)	3	0.96				
тс	TA-1537	FDA 73-4	Н	8.68(186)	26	3.00				
TC	TA-1537	FDA 73-4	L	7.70(165)	16	2.08				
тс	TA-1538	FDA 73-4	H	4.34(144)	31	7.14				
TC	TA-1538	FDA 73-4	L	4.32(144)	26	6.02				

test compound high dose low dose NOTE: TC

Н

(c) =contamination present

percent survival



# IX. ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

DATE:	9-10	)-74			Strain TA-15	35		
Test	Organ	Compound	Concentration	Total Cells/ mlx10 <sup>8</sup>	<u>his+</u> Revertants/ ml	his+ Revertants/10 <sup>8</sup> Survivors		
PC	<u>Li</u>	DMNA	100 μmoles/ml	4.11	4,449	1082.48		
	Lu	DMNA	100 μmoles/ml	2.59	24	9.27		
<del> </del>	T	DMNA	100 umoles/ml	4.14	22	5.31		
SC	-	DMNA	100 µmoles/ml	3.37	6	1.78		
	•	SALINE	•	3.84	8	2.08		
DATE:	9-23-	74		7	Strain TA-15:	37		
Test	Organ	Compound	Concentration	Total Cells/ mlxi08	his+ Revertants/ ml	his+ Revertants/10 <sup>8</sup> Survivors		
PC	<u>Li</u>	AAF	1.25 mg/ml	4.64	80	17.24		
	Lu	AAF	1.25 mg/ml	5.76	10	1.74		
	<u> </u>	AAF	1.25 mg/ml	5.04	22	4.37		
SC	_	AAF:	1.25 mg/ml	5.24	41	7.82		
	-	DMS0	· ·	6.01	41	6.82		
DATE:	9-24-74	(Repeated	i Compounds)	Strain TA-1538				
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his</u> + Revertants/ ml	<u>his+</u> Revertants/10 <sup>8</sup> Survivors		
PC	Li	AAF .	1.25 mg/ml	4.26	181	42.49		
	<u>Lu</u>	AAF	1.25 mg/ml	2.04	7	3.43		
	T	AAF	1.25 mg/ml	3.55	6	1.70		
SC		AAF	1.25 mg/ml	1.46	24	16.44		
		DMSO	•	2.85	37	12.98		
NOTE:	SC = AAF = DMNA = Li = Lu =	2-acetylam dimethylni liver lung	d chemical contro inofluorene	ols	(c) = contami	nation present		
		testes dimethyl s	ulfoxide		Project	No. 2468		

BIONETICS

# ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

SPECIE	S: Mouse			:		٠.
DATE:	9/10/74			S	train TA-15	
Test	Organ	Compound	Concentration	Total Cells/ R mlxl0 <sup>8</sup>	his+ evertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors
TC	Li	FDA 73-4	Н	3.61 (94)	12	3.32
			L	3.22 (84)	17	5.28
•	<u>Lu</u>	FDA 73-4	H	3.25 (85)	9 .	2.77
			L	2.76(72)	4	1.45
٠		FDA 73-4	Н	3.78(98)	20	5.29
			L	3.64(95)	13	3.57
DATE:	9/23/74			S	train TA-15	37
TC	Li	FDA 73-4	Н	5.15(86)	13	2.52
			L	4.14(69)	15	3.62
	<u>Lu</u>	FDA 73-4	Н	4.35(72)	8	1.84
			L	5.64(94)	8	1.42
•	<u>T</u>	FDA 73-4	Н	4.53(75)	27	5.96
			L	5.12(85)	41	8.01
DATE:	9/24/74			S	train TA-15	38
TC	Li	FDA 73-4	н	2.80(98)	11	3.93
			L	2.34(82)	36	15.38
	Lu	FDA 73-4	Н	2.59(91)	27	10.43
			L	3.03(106	) 35	11.55
•	T	FDA 73-4	Н	4.18(147	) 30	7.18
			1	2.28(80)	47	20.61

NOTES: H =

9

Annaged at 19

high dose low dose test compound liver TC =

lung testes

contamination present

percent survival



# ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

DATE:	9-1	3-74			Strain TA-15	35		
Test	Organ	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors		
PC	<u>Li</u>	DMNA	100 μmoles/ml	3.83	1,342	350.39		
	<u>Lu</u>	DMNA	100 µmoles/ml	4.34	` 9	2.07		
	<u> </u>	DMNA	100 μmoles/ml	3.39	15	4.43		
SC	-	DMNA	_100 μmoles/ml	3.14	5	1.59		
<del></del>		SALINE	-	4.13	7	1.70		
DATE:	9-25	-74			Strain TA-15	37		
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his+</u> Revertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors		
PC	<u>L1</u>	AAF	1.25 mg/ml	4.93	146	29.62		
•	<u> </u>	AAF	1.25 mg/ml	5.15	64	12.43		
	T	AAF	1.25 mg/ml	4.87	79	16.22		
SC		AAF	1.25 mg/ml	6.30	110	17.46		
	<del></del>	DMS0		6.93	67	9.67		
DATE:	9-24	-74			Strain TA-1538			
Test	Organ	Compound	Concentration	Total Cells/ mlx108	<u>his+</u> Revertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors		
PC	<u>Li</u>	AAF	1.25 mg/ml	3.26	137	42.02		
•	Lu	AAF	1.25 mg/ml	3.18	33	10.38		
<u></u>	T	AAF	1.25 mg/ml	2.30	37	16.09		
SC		AAF	1.25 mg/ml	1.46	24	16.44		
······································	•	DMSO	-	2.85	37	12.98		

AAF = 2-acetylaminofluorene DMNA = dimethylnitrosamine

Li = liver Lu = lung

T = testes DMSO = dimethyl sulfoxide



# ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

DATE.	0./3.0			C.A.	in TA 15	10°	
DATE:	9/13	//4		Σ	rain TA-15	A-1535	
Test	Organ	Compound	Concentration	Total Cells/ Re mlx10 <sup>8</sup>	his+ vertants/ ml	<u>his</u> + Revertants/10 <sup>6</sup> Survivors	
TC	Li	FDA 73-4	Н	3.29(80)	4	1.22	
			L	2.80(68)	7	2.50	
	Lu	FDA 73-4	Н	3.79(92)	4	1.06	
			L	3.23(78)	3	0.93	
		FDA 73-4	Н	3.47(84)	11	3.17	
		•	L	3.64(88)	14	3.85	
DATE:	9/25	/74		St	rain TA-15	37	
TC _	<u>Li</u>	FDA 73-4	Н	5.11(73)	38(c)	7.44	
			L	4.73(68)	26	5.50	
	Lu	FDA 73-4	Н	5.13(74)	44	8.58	
			L	5.05(73)	60	11.88	
	T	FDA 73-4	Н	5.63(81)	32	5.68	
			L	4.95(71)	48	9.70	
DATE:	9/24	/74		St	rain TA-15	38	
TC	Li	FDA 73-4	Н	0.60(2)	11	18.33	
			L	4.19(147)	58	13.84	
	Lu *	FDA 73-4	Н	2.04(72)	43	21.08	
			L	4.22(148)	55	13.03	
	T	FDA 73-4	Н	1.98(69)	15(c)	7.58	
			<u> </u>	3.39(119)	44	12.98	

NOTES: H = high dose L = low dose

, seattle .

7000

177

and the same

TC = test compound

Li = liver

Lu = lung T = testes

(c) = contamination present

] = percent survival



# ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS: POSITIVE AND SOLVENT CONTROL RESULTS

DATE:	10-	1-74			Strain TA-15	1535		
Test	Organ	Compound	Concentration	Total Cells/ mlx10 <sup>8</sup>	<u>his</u> + Revertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors		
PC	<u>Li</u>	DMNA	100 µmoles/ml	5.33	1,600	300.19		
	· <u>Lu</u>	DMNA	100 μmoles/ml	5.91	10	1.69		
	T	DMNA	100 µmoles/ml	5.91	5	0.85		
SC	**	DMNA	100 μmoles/ml	4.24	9	2.12		
	***	SALINE	•	5.24	9	1.72		
DATE:	9-25-74				Strain TA-15	37		
Test	Organ	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors		
PC	_Li	AAF	1.25 mg/ml	3.90	95	24.36		
	Lu	AAF	1.25 mg/ml	2.95	22	7.46		
<del></del>	Ţ	AAF	1.25 mg/ml	5.29	28	5.29		
SC		AAF	1.25 mg/ml	3.18	25	7.86		
<del></del>		DMS0	_	2.66	15	5.64		
DATE:	10-4-	-74			38			
Test	Organ	Compound	Concentration	Total Cells/ mlx108	his+ Revertants/ ml	<u>his</u> + Revertants/10 <sup>8</sup> Survivors		
PC	<u>Li</u>	AAF	1.25 mg/ml	6.50	197	30.31		
	<u>Lu</u>	AAF	1.25 mg/ml	6.87	86	12.52		
	T.	AAF	1.25 mg/ml	4.36	69	15.83		
SC	_	AAF	1.25 mg/ml	4.90	84	17.14		
	_	DMSO		5.55	71	12.79		
NOTE:	SC = AAF = DMNA = Li = Lu = T	positive co solvent and 2-acetylami dimethylnit liver lung testes dimethyl su	i chemical contro nofluorene crosamine	ls		nation present		
					Project N	0. 2468		

# ACTIVATION SUSPENSION TESTS WITH SALMONELLA INDICATOR STRAINS

DATE:	10/1	1/74		Strain TA-1535				
Test	Organ	Compound	Concentration	Total Cells/ F mlx10 <sup>8</sup>	his+ Revertants/ ml	his+ Revertants/10 <sup>6</sup> Survivors		
TC	<u>L,i</u>	FDA 73-4	Н	4.58(87)	2	0.44		
	4		L	5.68(108	) 2	0.35		
	Lu	FDA 73-4	Н	5.85(112	) 0			
			L	4.30(82)	7	1.63		
	T	FDA 73-4	Н	6.83(130	) 3	0.44		
			L .	5.32(102	) 0			
DATE:	9/25	/74		S	train TA-15	37		
TC .	Li	FDA 73-4	Н	3.62(136	) 15	4.14		
	-		L.	4.82(181	) 20	4.15		
	<u>Lu</u>	FDA 73-4	Н	3.98(150	)10	2.51		
			<b>L</b>	5.04(189	) 11	2.18		
		FDA 73-4	н	3.99(150	) 14	3.51		
	· · · · · · · · · · · · · · · · · · ·		L	4.60(173	) 27	5.87		
DATE:	10/4	/74		S	train TA-15	38		
TC	<u>Li</u>	FDA 73-4	Н	4.53(82)	45	9.93		
			L	5.10(92)	75	14.71		
	Lu ~	FDA 73-4	Н	6.29(113)	) 56	8.90		
			L	7.56(136)	87	11.51		
		FDA 73-4	Н	7.83(141	) 54	6.90		
			L	6.12(110	) 84	13.73		

NOTES: H =

1

To any other Park

high dose low dose test compound TC =

liver lungtestes

contamination present

percent survival



### NON-ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4 X.

	•	•		DATE:	9-16-74	1	
				Strai	n D4		
Test	Compound	Concentration	Total Population Screened <sup>a</sup>	Numb Conve Ade <sup>+</sup>	er of rtants <sup>b</sup> Try <sup>†</sup>	Converta 105 Sur Ade <sup>+</sup>	nts Per vivors Try <sup>+</sup>
PC	EMS	1.0 %	6.94	189	271	27.23	39.05
SC	Saline	-	7.69	27	38	3.51	4.94

= positive control NOTE: PC

SC = solvent control
EMS = ethyl methanesulfonate

= number  $\times 10^5$ = number at  $10^{-1}$  dilution

(c) = contamination present



### NON-ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

				DATE: 9/16/74				
				Strain D4				
Test	Compound	Concentration	Total Population Screened <sup>a</sup>	Number Convertants Ade <sup>+</sup> Try <sup>+</sup>	Convertants Per 10 <sup>5</sup> Survivors Ade <sup>†</sup> Try <sup>†</sup>			
тс	FDA 73-4	H	7.16 (93)	25 20	3.49 2.79			
		L	7.18 (93)	32 26	4.46 3.62			

NOTE: TC = test compound

H = high dose
L = low dose

a = number x 10<sup>5</sup>
b = number at 10<sup>-1</sup> dilution

(c) = contamination present
percent survival



# I. ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

SPEC	IES: Mou	ıse			DATE: 9-19-74				
				. (	Strai	n D4			
Test	Organ	Compound Concentrati		Total Population Screened <sup>a</sup>	Number of Convertants <sup>b</sup> Ade <sup>†</sup> Try <sup>†</sup>		Convertants Per 10 <sup>5</sup> Survivors Ade <sup>†</sup> Try <sup>†</sup>		
PC	Li	DMNA	150 μmoles/ml	5.16	82	77	15.89	14.92	
	Lu	DMNA	150 µmoles/ml	4.93	13	10	2.64	2.03	
	T	DMNA	150 μmoles/ml	5.10	11	6	2.16	1.18	
SC		DMNA	150 μmoles/ml	6.51	20	26	3.07	3.99	
	· •	SALINE	-	6.47	37	22	5.72	3.40	

NOTE: PC

= positive control
= solvent and chemical controls SC

DMNA = dimethylnitrosamine

= liver Li = lung Lu

= testes

= number x 10<sup>5</sup> = number at 10<sup>-1</sup> dilution a

= contamination present



# ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

SPEC	IES: N	louse		DATE: 9/19/74					
					Strain	n D4			
Test	Organ	Compound	Concentration	Total Population Screened <sup>a</sup>	Number Conyer Ade	er of rtants <sup>b</sup> Try <sup>+</sup>	Convertan 10 <sup>5</sup> Surv Ade <sup>+</sup>	ts Per ivors Try <sup>+</sup>	
TC	Li	FDA 73-4	Н	1.82(28)	12	. 6	6.59	3.30	
			L	(c)4.70(73)	16(c)	16	3.40	3.40	
	Lu	FDA 73-4	Н	2.77(43)	7	7	2.53	2.53	
			L	4.88(75)	15	18	3.07	3.69	
	T	FDA 73-4	Н	2.93(45)	13	19	4.44	6.49	
			L	(c)5.23(81)	20	19	3.82	3.63	

NOTE:

TC = test compound

H = high dose

L = low dose

Li = liver

Lu = lung

= testes

a = number x 10<sup>5</sup> b = number at 10<sup>-1</sup> dilution (c)= contamination present

)= percent survival



# ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

SPEC	IES: R	at		DATE: 10-18-74				
	Н	igh Dose	· · · · · · · · · · · · · · · · · · ·	1	Strain D4			
Test	Organ	Compound	Concentration	Total Population Screened <sup>a</sup>	Number Converta Ade <sup>+</sup> 1		Convertan 10 <sup>5</sup> Surv Ade <sup>+</sup>	
PC	PC Li	Li DMNA 150 μmoles/m	150 μmoles/ml	7.93	78	75	9.84	9.46
	Lu	DMNA	150 µmoles/ml	7.99	33	27	4.13	3.37
	T	DMNA	150 µmoles/ml	9.03	36 (c)	31 (	(c) 3.99	3.43
SC		DMNA	150 μmoles/ml	8.74	42 (c)	31 (	(c) 4.81	3.55
		SALINE	_	7.13 (c)	43 (c)	24	6.03	3.37

NOTE: PC

= positive control
= solvent and chemical controls SC

DMNA = dimethylnitrosamine

Li = liver Lu = lung T = testes

a

= number x 10<sup>5</sup> = number at 10<sup>-1</sup> dilution = contamination present



# ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

SPEC	IES: R	at		DATE: 10/18/74					
	Н	igh Dose		Strain D4					
Test	Organ	Compound	Concentration	Total Population Screened <sup>a</sup>		per of ertants <sup>b</sup> Try <sup>†</sup>		ertants Per Survivors Try <sup>+</sup>	
TC	Li	Li FDA 73-4	Н	5.62 (79)	20	14	3.56	2.49	
	•		. L		·	-			
	Lu	FDA 73-4	Н	5.94 (83)	21	19	3.54	3.20	
* -			L						
	T	FDA 73-4	Н	5.85 (82)	19	24	3.25	4.10	
			L,		· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	·	<del></del>	

NOTE:

TC = test compound
H = high dose
L = low dose

Li = liver

Lu = lung

= testes

a = number x 10<sup>5</sup>
b = number at 10<sup>-1</sup> dilution
(c)= contamination present

( )= percent survival



# ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

CDFC	[ES: Rat	· t		DATE: 9-26-74						
31 1.0			·	(	Strain	1 D4		·		
Test	Lov Organ	v Dose Compound	Concentration	Total Population Screened <sup>a</sup>		er of rtants <sup>b</sup> Try <sup>+</sup>	Converta 10 <sup>5</sup> Sur Ade <sup>+</sup>	nts Per vivors Try <sup>+</sup>		
PC		DMNA .	150 μmoles/ml	5.85	73	70	12.48	11.97		
, ,	Lu	DMNA	150 μmoles/ml	5.81	31	11	5.34	1.89		
	T	DMNA	150 μmoles/ml	5.00	32	19	6.40	3.80		
SC		DMNA	150 μmoles/ml	5.27	31	23	5.88	4.36		
J.	**	SALINE		5.50	28	20	5.09	3.64		

NOTE: PC

= positive control
= solvent and chemical controls SC

DMNA = dimethylnitrosamine

= liver Li = lung Lu = testes

= number x 10<sup>5</sup> = number at 10<sup>-1</sup> dilution (c) = contamination present



# ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4

	-	Low Dose		Strain D4					
Test	Organ	Compound	Concentration	Total Population Screened <sup>a</sup>		ber of ertants <sup>b</sup> Try <sup>†</sup>	Conver 10 <sup>5</sup> S Ade <sup>+</sup>	tants Per urvivors Try	
TC	Li		Н						
		FDA 73-4	· L	5.52 (100)	28	16	5.07	2.90	
	Lu		Н			·		•	
•		FDA 73-4	L	5.24 (95)	19	0	3.63		
	T		H	<del></del>				<del></del>	
		FDA 73-4	L	5.75 (105)	24	14	4.17	2.44	

= high dose = low dose

Li = liver

Commence of the Commence of th

Landing Co.

Lu = lung · T = testes

a = number x 10<sup>5</sup>
b = number at 10<sup>-1</sup> dilution
(c)= contamination present

( )= percent survival



# ACTIVATION SUSPENSION TESTS WITH SACCHAROMYCES INDICATOR STRAIN D4: POSITIVE AND SOLVENT CONTROL RESULTS

SPEC	IES: Mo	nkey		·	DATE:	10-22-7	4	
<u>.</u>				•	Strai	n D4		
Test	Organ	Compound	Concentration	Total Population Screened <sup>a</sup>		er of rtants <sup>b</sup> Try <sup>+</sup>	Convertants Per 10 <sup>5</sup> Survivors Ade <sup>†</sup> Try <sup>†</sup>	
PC	Li	DMNA	150 µmoles/ml	5.88	68	67	11.56	11.39
	Lu	DMNA	150 µmoles/ml	5.26	30	28	5.70	5.32
	Ţ	DMNA	150 µmoles/ml	5.85	3]	40	5.30	6.83
SC	-	DMNA	150 µmoles/ml	4.89	27	44	5.52	9,00
	-	SALINE	<b>-</b>	4,14	34	35	7.95	8.21

= positive control NOTE: PC

SC = solvent and chemical controls DMNA = dimethylnitrosamine

Li = liver Lu = lung = testes

= number x 10<sup>5</sup> = number at 10<sup>-1</sup> dilution

= contamination present



### **ACTIVATION SUSPENSION TESTS** WITH SACCHAROMYCES INDICATOR STRAIN D4

SPECIES:		Monkey		DATE: 10/22/74				
					Strai	n D4	<del></del>	
Test	Organ	Compound	Concentration	Total Population Screened <sup>a</sup>		er of rtants <sup>b</sup> Try <sup>†</sup>	Conve 10 <sup>5</sup> Ade <sup>+</sup>	rtants Per Survivors Try <sup>+</sup>
TC Li	Li	FDA 73-4	Н	5.38 (130)	23	18(c)	4.28	3.35
			. <b>L</b>	7.30 (176)	28(c)	32(c)	3.84	4.38
	Lu	FDA 73-4	Н	4.04 (98)	19	27	4.70	6.68
			L	5.88 (142)	28	27	4.76	4.59
	T	FDA 73-4	Н	4.07 (98)	30	17	7.37	4.18
			L	5.37 (130)	19	21	3.54	3.91

NOTE:

TC = test compound H = high dose L = low dose

Li = liver

Lu = lung

= testes

a = number x 10<sup>5</sup>
b = number at 10<sup>-1</sup> dilution
(c)= contamination present

}= percent survival



# XII. SUMMARY OF TEST RESULTS

COMPOUND FDA 73-4

## A. Suspension Tests

	Activa	tion .			lmonella Rev equencies (x			D4 Conversions (x 10 <sup>-5</sup> )
Testa	Species <sup>b</sup>	Organ <sup>C</sup>	·	TA-1535	TA-1537	TA-1538	Ade+	Try <sup>+</sup>
NA-PC NA-NC	<u>-</u>	- -	•	604.73 1.83	292.93 7.94	72.68 4.32	27.23 3.51	39.05 4.94
NA-H NA-L		-		2.48 0.96	3.00 2.08	7.14 6.02	3.49 4.46	2.79 3.62
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- M M M	- Li Lu T	,	2.08 1.78 1082.48 9.27 5.31	6.82 7.82 17.24 1.74 4.37	12.98 16.44 42.49 3.43 1.70	5.72 3.07 15.89 2.64 2.16	3.40 3.99 14.92 2.03 1.18
A-H A-L A-H A-L A-H A-L	M M M	Li Lu T		3.32 5.28 2.77 1.45 5.29 3.57	2.52 3.62 1.84 1.42 5.96 8.01	3.93 15.38 10.43 11.55 7.18 20.61	6.59 3.40 2.53 3.07 4.44 3.82	3.30 3.40 2.53 3.69 6.49 3.63
NC = n PC = p A = a H = h	on activation active conto con	rol	b M Mo R	= mouse = monkey = rat	c Li Lu T	= liver = lung = testes		nt control cal control

K K

# B. <u>Plate Tests</u>

	Activa	tion	<u>Sa1r</u>	nonella Respons	ses
Test <sup>a</sup>	Species <sup>b</sup>	Organ <sup>C</sup>	TA-1535	TA-1537	TA-1538
NA-PC NA-NC	-	•	+	<del>†</del>	<del>+</del>
NA-H		• . •	-	•	<b>-</b>
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- M M M	- Li Lu T	+	+	+
А-Н	M	L1	<b>**</b>		-
А-Н	M .	Lu	-	~	min .
А-н	M	T	•• •	<del>.</del>	<u>.</u>
PC = positive	control	b M = mous Mo = monk R = rat	ey Lu	= liver = lung = testes	(-C) = solvent control (+C) = chemical contro
A = activati H = high dos L = low dose	se .		·		48.

## SUMMARY OF TEST RESULTS

COMPOUND FDA 73-4

### A. Suspension Tests

	Activation			Salmonella Reversion Frequencies (x 10 <sup>-8</sup> )			s D4 Conversion es (x 10 <sup>-5</sup> )
Testa	Species <sup>b</sup>	Organ <sup>C</sup>	TA-1535	TA-1537	TA-1538	Ade+	Try <sup>+</sup>
NA-PC NA-NC	- -	-					
NA-H NA-L	-	. <del>-</del> ·					
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- R R R	- Li Lu T	1.70 1.59 350.39 2.07 4.43	9.67 17.46 29.62 12.43 16.22	12.98 16.44 42.02 10.38 16.09	6.03(5.09) 4.81(5.88) 9.84(12.48) 4.13(5.34) 3.99(6.40)	3.37(3.64) 3.55(4.36) 9.46(11.97) 3.37(1.89) 3.43(3.80)
A-H A-L A-H A-L A-H A-L	R R R	Li Lu T	1.22 2.50 1.06 0.93 3.17 3.85	7.44 5.50 8.58 11.88 5.68 9.70	18.33 13.84 21.08 13.03 7.58 12.98	3.56 5.07 3.54 3.63 3.25 4.17	2.49 2.90 3.20 0.00 4.10 2.44
NC = n PC = p A: = a H = h	on activation of the control of the	tro1 ·	b M = mouse Mo = monkey R = rat	C Li Lu T	= liver = lung = testes		nt control cal control

Two sets of D4 controls are shown: High dose (no parentheses) and low dose (parentheses).

COMPOUND FDA 73-4

# B. Plate Tests

	<u>Activation</u>				Salmonella Responses					
<u>Test<sup>a</sup></u>	S	peciesb	Organ <sup>C</sup>		TA-1535	TA-1537	TA-1538			
NA-PC NA-NC		-	-							
NA-H	·	•	·							
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	}	- - R R R	- ' - L1 Lu T		- - + -	- + -	- - + -			
A-H A-H		R R ′	L1 Lu		-	<del>-</del>	<b>-</b>			
А-Н	•	R	T		-	-	<b>-</b>			
a NA = NC = PC = A = H = L =	non activat negative co positive co activation high dose low dose	ntrol	Ь <sub>М</sub> Мо R	o = monkey	c L1 = Lu = T =	liver lung testes	(-C) = solvent control (+C) = chemical control			
						•	Project No. 2468			

# SUMMARY OF TEST RESULTS

COMPOUND FDA 73-4

## A. <u>Suspension Tests</u>

	Activation			Salmonella Reversion Frequencies (x 10 <sup>-8</sup> )			Saccharomyces D4 Conversion Frequencies (x 10-5)	
Testa	Species <sup>b</sup>	Organ <sup>C</sup>		TA-1535	TA-1537	TA-1538	Ade <sup>+</sup>	Try <sup>+</sup>
NA-PC NA-NC	-	-				•		
NA-H NA-L	•	- -				·		
A-NC (-C) A-NC (+C) A-PC A-PC A-PC	- Mo Mo Mo	- Li Lu T	<b>,</b>	1.72 2.12 300.19 1.69 0.85	5.64 7.86 24.36 7.46 5.29	12.79 17.14 30.31 12.52 15.83	7.95 5.52 11.56 5.70 5.30	8.21 9.00 11.39 5.32 6.83
A-H A-L A-H A-H A-L	Mo Mo Mo	L1 Lu T		0.44 0.35 0.00 1.63 0.44 0.00	4.14 4.15 2.51 2.18 3.51 5.87	9.93 14.71 8.90 11.51 6.90 13.73	4.28 3.84 4.70 4.76 7.37 3.54	3.35 4.38 6.68 4.59 4.18 3.91
NC = ne PC = pc A = ac H = hi	on activation active contositive contositive contositive contositive contositive dose	rol	b M Mo R	= mouse = monkey = rat	C L1 Lu T	= liver = lung = testes	(-C) = solven (+C) = chemic	t control

COMPOUND FDA 73-4

R.	Plate	Tests

B. Plate Test		. L.i. a.a.	-	Salmonella Responses			
<b>1</b>	<u>Activa</u> Species <sup>b</sup>	Organ <sup>C</sup>		TA-1535	TA-1537	TA-1538	
NA-PC NA-NC	-	-					
A-NC (-C) A-NC (+C) A-PC A-PC A-PC A-H	Mo Mo Mo Mo Mo	- Li Lu T Li		+			
NC = ne	Mo n activation gative control sitive control tivation	T b	M = mouse Mo = monkey R = rat	C Li Lu T	= liver = lung = testes	(-C) = solvent control (+C) = chemical contro	
u = hi	gh dose w dose				· .	Project No. 2468	

### XIII. INTERPRETATION AND CONCLUSIONS

Compound FDA 73-4, Potassium Sorbate, was examined for genetic activity in a series of in vitro microbial assays with and without metabolic activation. The following results were obtained.

- A. Salmonella typhimurium
- 1. Plate Tests

At a concentration of 2.5% (w/v), FDA 73-4 did not induce reversion in any of the three indicator strains.

2. Non-activation Suspension Tests

All tests were negative.

3. Activation Suspension Tests

All tests were negative.

- B. <u>Saccharomyces cerevisiae</u>
- 1. Non-activation Suspension Tests

All tests were negative.

2. Activation Suspension Tests

All tests were negative.

C. Additional Comments

None.

### D. Conclusions

FDA 73-4, Potassium Sorbate, did not demonstrate any detectable genetic activity in the tests used in this evaluation.

David Brusick

Director

Department of Genetics



## <u>APPENDIX</u>

SUMMARY OF TESTS EVALUATING DMSO FOR GENETIC ACTIVITY IN SALMONELLA AND SACCHAROMYCES



### COMPOUND DIMETHYSULFOXIDE

Α.	Suspension	Tests

<u>Jaspenston</u>	Activation			a Reversion es (x 10 <sup>-8</sup> )	Saccharomyces D4 Conversion Frequencies (x 10 <sup>-5</sup> )	
Test	Species <sup>a</sup>	Organ <sup>b</sup>	TA-1535	TA-1538	. Ade+	Try <sup>+</sup>
Non-activation				•		
Control (-C) High Dose <sup>C</sup> Low Dose <sup>d</sup>	-	- -	0.74 1.91 0.53	0.88 1.05 1.37	32.51 28.32 40.73	4.34 2.95 0.49
Activation						•
Control (+C) Control (-C)	÷ ·	- )	1.80 1.43	0.36 1.04	38.27 37.12	2.47 2.64
High Dose <sup>C</sup>	M M M	Li Lu T	0.34 0.59 0.62	1.07 0.58 0.30	47.77 36.29 34.35	2.75 1.39 1.94
Lose Dose <sup>d</sup>	M M M	Li Lu T	- 0.43 0.11	0.87 3.14 0.39 •	34.02 42.30 45.95	1.18 1.40 2.32

	\								Y	
Nota	(_C) =	calvant	control	and	(TC) =	+ + + + + + + + + + + + + + + + + + + +	Chamiasi	Acntmal		homogenate
11000	\~~ <i>\</i> _	201 ACII P	CONTENT	anu	\TU/ -	・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・	CHEMICAL	CONCLOI	WILHOUL	nomodenate

a M = mouse
Mo = monkey
R = rat

d Bacteria = 1.5% Yeast = 2.5%

### COMPOUND DIMETHYSULFOXIDE

# B. <u>Plate Tests</u>

	^ Activa	tion	Salmonella Responses				
Test	Speciesa	Organ <sup>b</sup>	TA-1535	TA-1537	TA-1538		
Non-activation	1						
Control (-C) Test compound (3%)	-	-	- -	<del>-</del> -	-		
Activation				÷	# €		
Control (+C) Control (-C)	•	- <del>-</del>	<b>-</b> \ -\ -\ -\ -\ -\ -\ -\ -\ -\ -\ -\ -\ -\	<u>-</u> -	- -		
Test compound (3%)	. M M	Li Lu	<u>-</u>	<b>-</b>	<u>-</u>		
	M R R	T Li Lu		- -	- - -		
	R Mo Mo	T Li Lu	. <b>-</b>	<del>-</del> ر -	- -		
, 1•	, Mo	Ţ	• • • • • • • • • • • • • • • • • • •	•	-		
Note: (-C) = solvent co	ontrol and (+	C) = chemical con	trol without homo	genate	•		
		•					
a M = mouse Mo = monkey R = rat		Lu = 1u	ver ing istes		ες.		